Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Authors: B. Besse, E. Felip, R. Garcia Campelo, M. Cobo, C. Mascaux, A. Madroszyk, F. Cappuzzo, W. Hilgers, G. Romano, F. Denis, S. Viteri, D. Debieuvre, D. Galetta, E. Baldini, M. Razaq, G. Robinet, M. Maio, A. Delmonte, B. Roch, P. Masson, W. Schuette, A. Zer, J. Remon, D. Costantini, B. Vasseur, R. Dziadziuszko, G. Giaccone, M. Zemanová, B. Besse, C. Bonnet, J. Cadranel, C. Chouaid, A. Cortot, D. Debieuvre, B. Delclaux, F. Denis, B. Duchemann, C. El Kouri, F.R. Ferrand, M. Ginoux, W. Hilgers, A. Madroszyk, P. Masson, J. Mazieres, O. Molinier, D. Moro-Sibilot, E. Pichon, C. Mascaux, G. Robinet, B. Roch, G. Zalcman, G. Schmidtke-Schrezenmeier, W. Schuette, L. Urban, M. Gottfried, H. Nechushtan, N. Peled, M. Wollner, A. Zer, E. Baldini, L. Bonanno, A. Bonetti, F. Cappuzzo, A. Delmonte, D. Galetta, M. Maio, V. Minotti, A. Rea, G. Romano, D. Tassinari, G. Tonini, R. Dziadziuszko, B. Karaszewska, A. Szczęsna, M. Cobo, J. De Castro, E. Felip, M.R. Garcia Campelo, A. Hernández, T. Moran, M. Provencio, S. Viteri, A. Dasgupta, N. Gabrail, G. Giaccone, A. Harshad, S. Liu, D. Oubre, R. Panikkar, M. Razaq, R. Sanborn
Journal: Annals of Oncology (2023)

Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients. ATALANTE-1 was a two-step open-label study to evaluate the efficacy and safety of OSE2101 compared to standard-of-care (SoC) chemotherapy (CT). Patients with human leukocyte antigen (HLA)-A2-positive advanced NSCLC without actionable alterations, failing sequential or concurrent CT and ICB were randomized (2 : 1) to OSE2101 or SoC (docetaxel or pemetrexed). Primary endpoint was overall survival (OS). Interim OS futility analysis was planned as per Fleming design. In April 2020 at the time of interim analysis, a decision was taken to prematurely stop the accrual due to coronavirus disease 2019 (COVID-19). Final analysis was carried out in all patients and in the subgroup of patients with ICB secondary resistance defined as failure after ICB monotherapy second line ≥12 weeks. Two hundred and nineteen patients were randomized (139 OSE2101, 80 SoC); 118 had secondary resistance to sequential ICB. Overall, median OS non-significantly favored OSE2101 over SoC {hazard ratio (HR) [95% confidence interval (CI)] 0.86 [0.62-1.19], P = 0.36}. In the secondary resistance subgroup, OSE2101 significantly improved median OS versus SoC [11.1 versus 7.5 months; HR (95% CI) 0.59 (0.38-0.91), P = 0.017], and significantly improved post-progression survival (HR 0.46, P = 0.004), time to Eastern Cooperative Oncology Group (ECOG) performance status deterioration (HR 0.43, P = 0.006) and Quality of Life Questionnaire Core 30 (QLQ-C30) global health status compared to SoC (P = 0.045). Six-month disease control rates and progression-free survival were similar between groups. Grade ≥3 adverse effects occurred in 11.4% of patients with OSE2101 and 35.1% in SoC (P = 0.002). In HLA-A2-positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to CT. Further evaluation in this population is warranted.